ARTICLE | Clinical News

Inecalcitol: Final Phase IIa data

September 27, 2010 7:00 AM UTC

Final data from an open-label, dose-escalation, French Phase IIa trial in 47 evaluable patients showed that 40 (85%) patients receiving up to 4 mg/day oral inecalcitol plus Taxotere docetaxel for up to 18 weeks had a >30% reduction in PSA levels within 3 months of starting treatment. Hybrigenics said the response rate compares favorably to the historical response rate of 65% for Taxotere alone. Two patients treated with 8 mg/day inecalcitol experienced sustained grade 3 hypercalcemia after 1-2 weeks of treatment. The MTD was 4 mg/day. ...